Literature DB >> 23568162

Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients.

M C Souza1, C A Rodrigues, M R R Silva, J Ribeiro, R Tognon, F A Castro, B P Simões, E X Souto, M L Chauffaille.   

Abstract

Primary myelofibrosis (PM) is a Philadelphia-negative clonal hematopoietic stem cell disorder characterized by intense reactive changes of bone marrow stroma with collagen fibrosis, osteosclerosis and angiogenesis. PM usually affects elderly people, and approximately half of the patients present JAK2V617F mutation. PM clinical course varies from 1 to 30 years, evolving from asymptomatic into progressive bone marrow failure, symptomatic splenomegaly or acute leukemia in 10-20 % of cases. PM risk stratification is based on parameters predicting survival, and several attempts have been made to identify clinical and laboratory features that could predict PM patient survival. This study applied five prognostic scores: Dupriez, Cervantes, Mayo, IPSS and DIPSS-Plus in 62 Brazilians patients from three centers, and compared their relevance and clinical usefulness considering the scores' parameters, fibrosis, JAK2V617F mutation, splenomegaly, hepatomegaly and treatment. According to the Cervantes, Dupriez and Mayo scores, most patients were stratified into low-risk group. However, when IPSS and DIPSS-Plus were applied, most patients were classified into an intermediate range, being low risk in only 11 and 13 % of patients, respectively. Overall survival at 4 years was 84 %. The Cervantes score was the only one that remained significantly associated with survival in a multivariate analysis. In conclusion, the Cervantes score remains important to the prognostication of PM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568162     DOI: 10.1007/s12032-013-0555-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.

Authors:  Kebede Hussein; Jocelin Huang; Terra Lasho; Animesh Pardanani; Ruben A Mesa; Cynthia M Williamson; Rhett P Ketterling; Curtis A Hanson; Daniel L Van Dyke; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2008-02-10       Impact factor: 2.997

2.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

Authors:  P Ljungman; M Bregni; M Brune; J Cornelissen; T de Witte; G Dini; H Einsele; H B Gaspar; A Gratwohl; J Passweg; C Peters; V Rocha; R Saccardi; H Schouten; A Sureda; A Tichelli; A Velardi; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2009-07-06       Impact factor: 5.483

3.  Anaemia in myelofibrosis: its value in prognosis.

Authors:  O S Njoku; S M Lewis; D Catovsky; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

4.  Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.

Authors:  Ayalew Tefferi; Jocelin Huang; Susan Schwager; Chin-Yang Li; Wenting Wu; Animesh Pardanani; Ruben A Mesa
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

5.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.

Authors:  B Dupriez; P Morel; J L Demory; J L Lai; M Simon; I Plantier; F Bauters
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

6.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

7.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

8.  A prognostic classification of myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; C Berzuini; L N Liberato; A Costa; G Polino; E Ascari
Journal:  Br J Haematol       Date:  1988-12       Impact factor: 6.998

9.  Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients.

Authors:  G Visani; C Finelli; U Castelli; M C Petti; P Ricci; N Vianelli; L Gianni; E Zuffa; M A Aloe Spiriti; R Latagliata
Journal:  Br J Haematol       Date:  1990-05       Impact factor: 6.998

10.  Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.

Authors:  Leonardo Caires Dos Santos; Juliana Corrêa da Costa Ribeiro; Neusa Pereira Silva; Janete Cerutti; Maria Regina Regis da Silva; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.